<DOC>
	<DOCNO>NCT00889603</DOCNO>
	<brief_summary>The Aricept® Evess study prospective , non-comparative , non-interventional study use Aricept® Evess treatment out-patients AD Vascular Dementia . The 24 week length study aim collect data large number patient ( n= 400 ) safety efficacy usual dosage product provide overview Aricept® Evess profile .</brief_summary>
	<brief_title>Non-Interventional Study With Aricept® Evess</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Outpatients ( male / female ) , old 50 year . Patients clinical symptom mild moderate AD Vascular Dementia . MMSE score 12 24 . Patients know hypersensitivity donepezil clorhydrat , piperidine derivative excipients Aricept® Evess . Patients severe impaired hepatic function . Patients preexist gastrointestinal ulcer disease . Patients history bronchial asthma chronic obstructive lung disease . Patients history serious atrioventricular conduction disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Aricept® Evess</keyword>
	<keyword>non-interventional study</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Vascular Dementia</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety .</keyword>
</DOC>